SA519410534B1 - أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها - Google Patents

أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها

Info

Publication number
SA519410534B1
SA519410534B1 SA519410534A SA519410534A SA519410534B1 SA 519410534 B1 SA519410534 B1 SA 519410534B1 SA 519410534 A SA519410534 A SA 519410534A SA 519410534 A SA519410534 A SA 519410534A SA 519410534 B1 SA519410534 B1 SA 519410534B1
Authority
SA
Saudi Arabia
Prior art keywords
lymphocyte attenuator
agonist antibodies
antibodies
treatment
attenuator
Prior art date
Application number
SA519410534A
Other languages
Arabic (ar)
English (en)
Inventor
شارليز فينديل اندريو
كرومين اتويل شان
اتش اوبونجو فيكتور
Original Assignee
ايلاي ليلى اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلاي ليلى اند كومباني filed Critical ايلاي ليلى اند كومباني
Publication of SA519410534B1 publication Critical patent/SA519410534B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SA519410534A 2017-05-19 2019-11-12 أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها SA519410534B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SA519410534B1 true SA519410534B1 (ar) 2023-11-08

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519410534A SA519410534B1 (ar) 2017-05-19 2019-11-12 أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها

Country Status (26)

Country Link
US (2) US10604573B2 (cg-RX-API-DMAC7.html)
EP (1) EP3625257A1 (cg-RX-API-DMAC7.html)
JP (2) JP6790304B2 (cg-RX-API-DMAC7.html)
KR (3) KR102294051B1 (cg-RX-API-DMAC7.html)
CN (3) CN110621699B (cg-RX-API-DMAC7.html)
AR (1) AR111752A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018269585B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019021547A2 (cg-RX-API-DMAC7.html)
CA (2) CA3064518A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003215A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012756A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190521A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000293A (cg-RX-API-DMAC7.html)
EA (1) EA201992460A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19082184A (cg-RX-API-DMAC7.html)
JO (1) JOP20190261A1 (cg-RX-API-DMAC7.html)
MA (1) MA49133A (cg-RX-API-DMAC7.html)
MX (1) MX381033B (cg-RX-API-DMAC7.html)
MY (2) MY197425A (cg-RX-API-DMAC7.html)
NZ (1) NZ758360A (cg-RX-API-DMAC7.html)
PE (1) PE20191843A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502575A1 (cg-RX-API-DMAC7.html)
SA (1) SA519410534B1 (cg-RX-API-DMAC7.html)
TW (4) TWI747043B (cg-RX-API-DMAC7.html)
WO (1) WO2018213113A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201906954B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
EP4469558A4 (en) * 2022-01-29 2026-02-25 Hifibio Inc Anti-BTLA antibodies and their uses in cancer treatment
AU2023212896A1 (en) * 2022-01-29 2024-08-22 Hifibio, Inc. Antibody against btla and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4626929A2 (en) * 2022-12-02 2025-10-08 Eli Lilly and Company Btla agonist antibodies and uses thereof
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells
WO2026053130A1 (en) * 2024-09-03 2026-03-12 Mirobio Limited Anti-btla antibodies and uses of the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
US7153950B2 (en) * 2002-10-25 2006-12-26 Genentech, Inc. Nucleic acids encoding an immune related polypeptide
MX2009005189A (es) * 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
JP7227007B2 (ja) * 2015-12-02 2023-02-21 ストサイエンシス, インコーポレイテッド グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体

Also Published As

Publication number Publication date
WO2018213113A1 (en) 2018-11-22
JP2021019642A (ja) 2021-02-18
AU2018269585A1 (en) 2019-10-31
EP3625257A1 (en) 2020-03-25
US10604573B2 (en) 2020-03-31
MX381033B (es) 2025-03-12
MY198277A (en) 2023-08-18
CN110621699A (zh) 2019-12-27
ZA201906954B (en) 2021-06-30
PE20191843A1 (es) 2019-12-31
AU2021277743A1 (en) 2021-12-23
TW201904991A (zh) 2019-02-01
TW202233681A (zh) 2022-09-01
JP7072622B2 (ja) 2022-05-20
DOP2019000293A (es) 2019-12-15
PH12019502575A1 (en) 2020-07-13
TW201946932A (zh) 2019-12-16
NZ758360A (en) 2022-10-28
US11396545B2 (en) 2022-07-26
CA3064518A1 (en) 2018-11-22
JP2020518288A (ja) 2020-06-25
CN117402245A (zh) 2024-01-16
CA3184628A1 (en) 2018-11-22
TWI677504B (zh) 2019-11-21
AU2018269585B2 (en) 2021-09-02
US20200239578A1 (en) 2020-07-30
KR102294051B1 (ko) 2021-08-27
EA201992460A1 (ru) 2020-03-18
US20180334502A1 (en) 2018-11-22
CN110621699B (zh) 2023-10-31
CL2019003215A1 (es) 2020-04-13
CO2019012756A2 (es) 2020-01-17
TWI804044B (zh) 2023-06-01
ECSP19082184A (es) 2019-11-30
JP6790304B2 (ja) 2020-11-25
MY197425A (en) 2023-06-16
CN117402244A (zh) 2024-01-16
TWI747043B (zh) 2021-11-21
MA49133A (fr) 2020-03-25
AR111752A1 (es) 2019-08-14
CR20190521A (es) 2020-01-06
TW202334237A (zh) 2023-09-01
KR20210106033A (ko) 2021-08-27
KR20220158847A (ko) 2022-12-01
KR20190140969A (ko) 2019-12-20
MX2019013604A (es) 2019-12-18
BR112019021547A2 (pt) 2020-05-12
JOP20190261A1 (ar) 2019-11-05

Similar Documents

Publication Publication Date Title
PH12019502575A1 (en) Btla agonist antibodies and uses thereof
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CY1123409T1 (el) Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων)
MX374853B (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso.
MX2021012307A (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso.
MX2020000960A (es) Anticuerpos anti-tigit.
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
BR112019012342A2 (pt) anticorpos il-11
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
MX2020003132A (es) Anticuerpos anti-ctla4 y usos de los mismos.
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
EA201992883A1 (ru) АНТИТЕЛА К TrkB
MX2018000073A (es) Agonistas de proteina de fusion btla y usos de los mismos.
EA201990253A1 (ru) Гуманизированные антитела против s100a9 и их применение
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
EA202090309A1 (ru) Анти-tigit антитела
EA202090929A1 (ru) Антитела, активируемые антитела, биспецифические антитела и биспецифические активируемые антитела и способы их применения